Flunazine

Manufacturer
Bimeda Inc. | Bimeda-MTC Animal Health
Effective date
2024-03-13
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
9
Source
full-release
Hydrated at
2026-06-01 02:42:54

Label at a glance#

ProductFlunazine
Active ingredientFLUNIXIN MEGLUMINE
Label structure6 sections

Storage and handling

Store at 20°C - 25°C (68°F - 77°F); excursions permitted between 15°C - 30°C (between 59°F - 86°F) See product information sheet for additional information. Approved by FDA under ANADA # 200-581

Label contents#

Full prescribing information#

DESCRIPTION SECTION

Flunazine®
(flunixin meglumine paste)
Equine Paste

Apple Flavored

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Each 30-g syringe of Flunazine Equine Paste contains flunixin meglumine equivalent to 1500 mg flunixin.

INDICATIONS & USAGE SECTION

INDICATIONS: Flunazine Equine Paste is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.

ACTIVITY: Flunixin meglumine is a potent, nonnarcotic, nonsteroidal, analgesic agent with anti-inflammatory and antipyretic activity. It is significantly more potent than pentazocine, meperidine, and codeine as an analgesic in the rat yeast paw test. Oral studies in the horse show onset of flunixin activity occurs within 2 hours of administration. Peak response occurs between 12 and 16 hours and duration of activity is 24 to 36 hours.

WARNINGS AND PRECAUTIONS SECTION

For oral use in horses only
CONTRAINDICATIONS: There are no known contraindications to this drug when used as directed.
WARNING: Do not use in horses intended for human consumption.
PRECAUTIONS: The effect of flunixin meglumine on pregnancy has not been determined. Studies to date show there is no detrimental effect on stallion spermatogenesis with or following the recommended dose of flunixin meglumine.
SIDE EFFECTS: During field studies with flunixin meglumine, no significant side effects were reported.

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VET or online at www.fda.gov/reportanimalae

DOSAGE & ADMINISTRATION SECTION

DOSAGE AND ADMINISTRATION: The recommended dose of flunixin is 0.5 mg per lb of body weight once daily. The Flunazine Equine Paste syringe, calibrated in twelve 250-lb weight increments, delivers 125 mg of flunixin for each 250 lbs (see dosage table). One syringe will treat a 1000-lb horse once daily for 3 days, or three 1000-lb horses one time.

tabletable

* Use dial edge nearest syringe barrel to mark dose.

The paste is orally administered by inserting the nozzle of the syringe through the interdental space, and depositing the required amount of paste on the back of the tongue by depressing the plunger.

Treatment may be given initially by intravenous or intramuscular injection of Flunazine Injectable Solution, followed by Flunazine Equine Paste on Days 2 to 5. Flunixin meglumine treatment should not exceed 5 consecutive days.

TOXICITY: No toxic effects were observed in rats given oral flunixin meglumine 2 mg/kg per day for 42 days. Higher doses produced ulceration of the gastrointestinal tract. The emetic dose in dogs is between 150 and 250 mg/kg. Flunixin was well tolerated in monkeys dosed daily with 4 mg/kg for 56 days. No adverse effects occurred in horses dosed orally with 1.0 or 1.5 mg/lb for 5 consecutive days.

STORAGE AND HANDLING SECTION

Store at 20°C - 25°C (68°F - 77°F); excursions permitted between 15°C - 30°C (between 59°F - 86°F)
See product information sheet for additional information.

Approved by FDA under ANADA # 200-581

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LABELLABEL

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1603390flunixin 1500 MG Oral Paste [Flunazine]SBD9
1603384flunixin 1500 MG Oral PasteSCD9
1603390Flunazine 1500 MG Oral PasteSY9

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
61133-6007-1Flunazine30 g in 1 SYRINGEPASTE309

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
61133-6007FLUNAZINE (FLUNIXIN MEGLUMINE) PASTE [BIMEDA INC.]91 package rows20240315_ef38da06-9556-4841-8a72-e57c1f8a3e28.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
FLUNIXIN MEGLUMINEACTIVE INGREDIENT8Y3JK0JW3U5
FLUNIXINACTIVE MOIETY356IB1O4005

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
61133-600761133-6007-1

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Name, UNII, Kind table
NameUNIIKind
FLUNIXIN MEGLUMINE8Y3JK0JW3UACTIB

Source Document#

Source XML · Source PDF

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.